IPEX as a result of mutations in FOXP3 by Vliet, H.J. (Hans ) van der & Nieuwenhuis, E.E.S. (Edward)
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2007, Article ID 89017, 5 pages
doi:10.1155/2007/89017
Review Article
IPEX as a Result of Mutations in FOXP3
Hans J. J. van der Vliet1 and Edward E. Nieuwenhuis2
1Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
2Department of Pediatric Gastroenterology, ErasmusMedical Center, Sophia Childrens’ Hospital, 3000 GE Rotterdam, The Netherlands
Correspondence should be addressed to Hans J. J. van der Vliet, jj.vandervliet@vumc.nl
Received 3 July 2007; Revised 12 August 2007; Accepted 13 August 2007
Recommended by Y. Liu
Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare disorder caused by mutations in the
FOXP3 gene that result in the defective development of CD4+CD25+ regulatory T cells which constitute an important T cell subset
involved in immune homeostasis and protection against autoimmunity. Their deficiency is the hallmark of IPEX and leads to se-
vere autoimmune phenomena including autoimmune enteropathy, dermatitis, thyroiditis, and type 1 diabetes, frequently resulting
in death within the first 2 years of life. Apart from its clinical implications, IPEX illustrates the importance of immunoregulatory
cells such as CD4+CD25+ regulatory T cells.
Copyright © 2007 H. J. J. van der Vliet and E. E. Nieuwenhuis. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
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Immunodysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX) syndrome is a rare disorder that was first de-
scribed in [1]. It usually presents in the first few months of
life with dermatitis, mostly manifested by eczema, although
psoriatiform lesions and nodular pemphigoid have also been
described. Other symptoms include cachexia and growth re-
tardation as a result of the combination of autoimmune en-
teropathy, usually manifested by severe watery diarrhea, type
1 diabetes mellitus (DM), and chronic inflammation with ex-
cessive cytokine production [2]. In essence, IPEX is the result
of a severe dysregulation of the immune system that can also
lead to thyroiditis, hypothyroidism, autoimmune hemolytic
anemia, recurrent infections, and membranous nephropathy
[2, 3]. Without treatment, children usually die in the first 2
years of life due to sepsis or failure to thrive.
FOXP3
IPEX is an X-linked recessive disorder that is caused by
mutations in the FOXP3 gene that is located on the X-
chromosome (Xq11.23-Xq13.3) and consists of 11 coding
exons [4, 5]. After the initial discovery of this gene defect
in scurfy mice, which develop a disease highly homologous
to that of patients with IPEX, mutations were demonstrated
in the orthologous human gene [6]. IPEX might however be
genetically more heterogeneous than initially presumed as a
few patients with IPEX were found not to carry mutations
in FOXP3. Furthermore, in 1 family of patients that included
an affected female, IPEX was linked to an autosomal locus
[3, 7]. In these cases, IPEX could be the result of regulatory
or conditional mutations outside FOXP3 coding regions. In-
deed, Bennett et al. identified a mutation in a region follow-
ing the final coding exon, resulting in a reduction in FOXP3
mRNA expression [8].
To date, 20 mutations in FOXP3 have been identified
in patients with IPEX—most of which result in a change
in the amino acid sequence in the DNA-binding domain of
the FOXP3 protein [9–12]. Figure 1 shows a schematic view
of FOXP3 with locations of missense mutations indicated
by arrows. Mutations in the winged-helix/forkhead (FKH)
domain interfere with nuclear import and DNA binding,
critical to FOXP3 repressor activity, while mutations in the
leucine zipper impair FOXP3 dimerization, and hence DNA
binding [12, 13]. Functional domains within the N-terminal
half of FOXP3 have been identified and shown to be in-
volved in general transcriptional repression and repression
of NFAT-mediated transcription [12, 13]. It has also been
suggested that some mutations can lead to an increase in
the length of the carboxy terminus of FOXP3 resulting in a
change in the three-dimensional structure and the position
of the winged helix, or lead to a decrease in the stability of
FOXP3 mRNA [5, 8, 11].
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Figure 1: Schematic representation of human FOXP3. Arrows indicate the location of identified missense point mutations in patients with
IPEX.
The most important characteristic of FOX proteins is
the “forkhead box,” which consists of a sequence of 80–
100 amino acids that together form a DNA-binding motif.
The capacity to bind to DNA allows FOX proteins to reg-
ulate the expression of genes involved in cell growth, pro-
liferation, differentiation, and lifespan. FOXP3 codes a 48-
kD protein (431 amino acids) from the forkhead/winged-
helix transcription factor family, and it is highly expressed
in CD4+CD25+ regulatory T cells [14, 15]. This T cell subset
is involved in limiting the immune response of other cells,
for example, conventional T cells. As in conventional T cells,
activation of CD4+CD25+ regulatory T cells leads to the in-
duction of the transcription factor NFAT (nuclear factor of
activated T cells). In case of conventional T cells, T cell re-
ceptor signaling in combination with costimulation will re-
sult in binding of NFAT to AP-1 (activator protein 1), thereby
inducing transcription of genes involved in T cell activation.
In CD4+CD25+ regulatory T cells, however, NFAT preferen-
tially binds to FOXP3 and results in the transcription of a
whole different set of genes, resulting in immune suppres-
sion (Figure 2) [16].
CD4+CD25+ regulatory T cells
Immunosuppressive CD4+CD25+ regulatory T cells consti-
tute a small subset (5–10%) of CD4+ T (helper) cells that
develop in the thymus. They are characterized by the ex-
pression of the interleukin (IL) 2 receptor α-chain (CD25),
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and
glucocorticoid-induced TNF receptor (GITR). The most spe-
cific molecular marker of CD4+CD25+ regulatory T cells,
which is functionally involved in immune suppression, is
the FOXP3 protein. In the absence of FOXP3, CD4+CD25+
regulatory T cells do not develop. The mechanisms me-
diating the immunosuppressive effects in vivo have not
been fully elucidated. Several studies suggest immunosup-
pression to be cell contact-dependent, while other stud-
ies demonstrate that suppression can also be cell contact-
independent, for example, via the production of the im-
munosuppressive cytokines IL-10 and TGF-β, preferential
IL-2 consumption by CD4+CD25+ regulatory T cells, or di-
rect lysis of T cells via perforin and granzymes (Figure 3)
[10, 11, 14]. Noteworthily, the initiation of immunosuppres-
sion by CD4+CD25+ regulatory T cells requires antigen ex-
posure, but suppressive effects can extend through bystander
immunosuppression. CD4+CD25+ regulatory T cells have
been demonstrated to suppress various types of immune re-
sponses, including autoimmune, antimicrobial, and antitu-
mor immune responses (Figure 3) [14, 17].
IPEX
The incidence of IPEX is not known, but it is likely to be rare
although unfamiliarity with the disease might be a contribut-
ing factor [3]. Although the inheritance pattern of IPEX is
X-linked recessive in case of mutations in FOXP3 (with no
reported female patients, and asymptomatic female carriers
of the gene mutation), the disease might be genetically more
heterogeneous than initially presumed as a few patients with
IPEX were found not to carry mutations in FOXP3 . Further-
more, in 1 family of patients that included an affected female,
IPEX was suggested to be linked to an autosomal locus [3, 7].
Symptoms usually start in the perinatal period or in early
childhood, but they can also first arise in adulthood. First
symptoms usually include type 1 DM and secretory diar-
rhea or ileus. Additional symptoms include eczema, throm-
bocytopenia, (Coombs-positive) anemia, lymphadenopathy,
and thyroiditis/hypothyroidism. Renal insufficiency, caused
by glomerulopathy and interstitial nephritis, arthritis, and
ulcerative colitis have also been described in several cases. Pa-
tients with IPEX can be immunocompromised as a result of
the defect in immunoregulation, autoimmune neutropenia,
and immunosuppressive therapy. This can result in severe in-
fectious complications and sepsis (especially catheter related)
[1–3, 9].
Diagnosis
An important prerequisite for diagnosing IPEX is clini-
cal suspicion. In this regard, the family history can be of
value, though one has to realize that symptoms of the dis-
ease can vary within one family, for example, due to differ-
ences in FOXP3 regulating elements or differences in mod-
ifying genes, environment, or therapy. Laboratory evalua-
tion shows, depending on the exact presentation of dis-
ease, signs of type 1 DM, enteropathy, hypothyroidism,
and/or cytopenias. No consistent changes in the function
or number of “conventional” T cells, granulocytes, com-
plement system, or immunoglobulin concentrations have
been described. Histopathology shows the absence of nor-
mal mucosa of the small bowel and sometimes of the colon
with diffuse infiltration of inflammatory cells in the lam-
ina propria and submucosa. Inflammatory infiltrates can
also occur in other organs including pancreas, skin, and
kidney [3]. In the blood, autoantibodies can be detected
against erythrocytes, thyroid, and pancreas [18]. Defini-
tive diagnosis is based on DNA analysis showing mutations
in the FOXP3 gene, though immunocytochemical analysis
of FOXP3-expressing cells in bowel biopsies might provide
a more rapid screening tool [19]. As mentioned, to date,
20 mutations in FOXP3 have been identified [9, 10]. In
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Figure 2: FOXP3 regulates NFAT-mediated gene transcription in CD4+CD25+ regulatory T cells. In both conventional T cells (left) and
CD4+CD25+ regulatory T cells (right), T cell receptor-(TCR-) mediated activation upregulates the expression of the transcription factor
NFAT. Upon TCR stimulation and CD28-mediated costimulation, NFAT binds to AP-1 in conventional T cells but to FOXP3 in CD4+CD25+
regulatory T cells. As a consequence, activation results in the transcription of a different set of genes in both cell types.
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Figure 3: Schematic representation of the regulation of the function of effector T cells by CD4+CD25+ regulatory T cells. Upon antigen-
specific activation by dendritic cells (DCs), CD4+CD25+ regulatory T (Treg) cells can suppress immune responses through (a) preferential
consumption of IL-2 by CD4+CD25+ regulatory T cells instead of effector T cells, (b) induction of effector T cell apoptosis via CD30/CD30L
interactions or perforin/granzyme B (GrB), (c) production of immunosuppressive cytokines IL-10 and TGF-β by CD4+CD25+ regulatory T
cells, and (d) production of immunosuppressive tryptophane metabolites as a result of upregulation of indoleamine-2,3-dioxygenase (IDO)
in DC.
patients with a mild presentation of IPEX, a mutation in
FOXP3 was recently identified that did not interfere with
protein expression but that did result in a partial defect
in CD4+CD25+ regulatory T cell immunosuppression [10].
One of these patients presented at the age of 4 months with
dehydration as a result of severe enteritis, hemolytic ane-
mia, and eczema. Remarkably, symptoms disappeared with-
out immunosuppressive therapy and the patient, now 2 years
old, only incidentally complains of mild eczema. This pa-
tients’ brother carries the same mutation but he has not
shown any symptom of the disease (until at least 3.5 years
of age).
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Therapy
Apart from supportive care (including parenteral nutrition,
blood transfusions, and treatment of diabetes), immuno-
suppressive therapy and bone marrow transplantation have
shown efficacy. As a result of the rarity of the syndrome,
therapies have not been studied in large-scale clinical tri-
als, but in either small series or case reports. Various im-
munosuppressive medications have been administered suc-
cessfully in IPEX including high-dose steroids, cyclosporin
A, tacrolimus, methotrexate, infliximab, and rituximab [1],
reviewed in [3, 20–24]. Unfortunately, these immunosup-
pressants are usually only partially effective and the dose is
limited in large part by infectious complications and toxic-
ity [3, 20]. Sirolimus was suggested to be more effective as
it resulted in a sustained (followup up to 5 years) suppres-
sion of systemic inflammatory, gastrointestinal, and derma-
tologic symptoms of IPEX in 3 patients. However, these pa-
tients received sirolimus in combination with azathioprine or
methotrexate and received prior treatment with steroids and
tacrolimus [20]. A promising form of therapy seems bone
marrow transplantation, although the transplantation proto-
col probably needs further optimization. In several patients,
allogenous transplantation resulted in a rapid and sustained
reduction in symptoms of enteropathy, eczema, and diabetes
which was accompanied by a reduction in the concentra-
tion of autoantibodies directed against pancreas [18, 25]. In
several of these patients, a donor/acceptor chimerism was
found, suggesting that a limited number of healthy donor
leukocytes are sufficient to suppress the auto-immune pro-
cess [18, 25]. Noteworthily, transplanted patients do not al-
ways have an uncomplicated followup as one patient died af-
ter a disease-free interval of 29 months as a result of a lym-
phoproliferative hemophagocytic syndrome, while two other
patients died from infectious complications, probably due
to earlier long-term immunosuppressive treatment, after an
initial improvement in their clinical condition [3, 18]. Im-
portantly, recently beneficial results have been described in
4 patients who were treated with bone marrow transplan-
tation after a “reduced-intensity” conditioning regimen us-
ing alemtuzumab, fludarabine, and melphalan [26]. In all 4
patients, colitis and allergies subsided after transplantation,
and transplantation-related complications were mainly in-
fectious in the first phase, though in 1 patient, acute and sub-
sequent chronic graft-versus-host disease developed, which
necessitated immunosuppressive therapy with tacrolimus
[19]. It seems reasonable to consider transplantation in an
early phase of the disease as this might reduce the risk of in-
fectious complications of chronic immunosuppressive ther-
apy, and curtail the autoimmune damage to endocrine or-
gans.
CONCLUDING REMARKS
IPEX illustrates the central regulatory role of regulatory T
cells in the immune system. Importantly, apart from the
severe defects in CD4+CD25+ regulatory T cells that re-
sult in IPEX, other, perhaps more subtle, changes in the
CD4+CD25+ regulatory T cell population can contribute to
the pathogenesis of disease. In various autoimmune syn-
dromes, for example, quantitative or qualitative defects in
CD4+CD25+ regulatory T cells have been reported [2]. In
contrast, in various forms of cancer, an increase in the num-
ber of CD4+CD25+ regulatory T cells was noted and related
to downregulation of antitumor immune responses and poor
prognosis [27]. In this situation, a reduction in the num-
ber of CD4+CD25+ regulatory T cells could be beneficial, as
demonstrated by a study in which CD4+CD25+ regulatory T
cell depletion enhanced the antitumor immune response in
renal cell cancer [28]. Clearly, a further increase in knowledge
on the biology of regulatory T cells will likely result in new
therapeutic strategies for a specific set of immune-mediated
disorders.
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